Adamas leaders in the treatment of chronic neurologic disorders anoxic seizure

At adamas pharmaceuticals, inc., we seek to redefine the treatment experience for patients suffering anoxic seizure from chronic neurological diseases. Our vision is grand, our goal bold: to create and commercialize a new generation of medicines intended anoxic seizure to lessen the burden of disease on patients, caregivers and society. With a new commercial medicine and robust pipeline of investigational anoxic seizure programs focused on meaningfully differentiated treatment options for patients, we are well on our way. Our therapeutic targets include a broad range of neurologic diseases, including parkinson’s disease, multiple sclerosis, epilepsy and alzheimer’s disease.

Our treatment innovations stem from a deep scientific understanding of anoxic seizure time-dependent biology – the deliberate mapping of disease patterns and drug activity – along with a goal to meaningfully increase the efficacy of anoxic seizure known molecules without compromising tolerability. This approach is designed to ensure that our medicines fit anoxic seizure within, rather than define, people’s daily lives. Our goal is to develop medicines that are timed for anoxic seizure the benefit of patients.

Dr. Went is the founder, chairman, and CEO of adamas pharmaceuticals and has guided the company’s growth since its inception in 2000. Dr. Went developed the original scientific approach, based upon the understanding and modeling of time-dependent biological phenomena. He has steered adamas through the licensing of assets related anoxic seizure to namenda XR and namzaric to forest laboratories (now allergan), the company’s IPO, and steered the company through the development of gocovri and anoxic seizure the commercial launch of a new medicine for patients with anoxic seizure parkinson’s disease. Prior to adamas, dr. Went co-founded curagen corporation in 1992, one of the first genomics companies, where he served as executive vice president and director. He has served on the board of directors of angelica, parallele biosciences, and tethys biosciences.

Dr. Went has published in the fields of catalysis, spectroscopy, DNA sequencing, gene expression profiling, neuroscience, influenza, and neurology. An inventor with more than 70 issued and pending patents, he received his phd in chemical engineering from the university anoxic seizure of california, berkeley, his BS in chemical engineering from carnegie mellon university, and completed additional post-doctoral work at cornell university.

Vijay shreedhar joined adamas as chief commercial officer in may anoxic seizure 2019 from amgen inc. Where he served in a variety of sales and marketing anoxic seizure roles of increasing responsibility in multiple therapeutic areas. Most recently, vijay was executive director and integrated commercial lead for the anoxic seizure multiple myeloma franchise with responsibility for national sales, brand marketing and regional marketing teams. He brings extensive US product launch experience, successfully leading the market entry of new entities, expanded indications for approved products, as well as new drug-delivery systems. He has led strategy and execution for multiple brands, including neulasta®, XGEVA®, vectibix® and kyprolis®, with a demonstrated track record of generating robust demand growth anoxic seizure in highly competitive markets. Vijay started his professional career as a scientist in the anoxic seizure field of immuno-oncology, earning his phd at the university of texas, M.D. Anderson cancer center and gaining experience in both academic and anoxic seizure pharmaceutical research settings. He also earned an MBA in healthcare management from the anoxic seizure wharton school at the university of pennsylvania.

Ms. Rhodes joined adamas as general counsel and corporate secretary in anoxic seizure april 2016, and was subsequently appointed chief compliance officer and chief business anoxic seizure officer in august 2016 and january 2017, respectively. She previously served as general counsel at medivation, inc., where she was responsible for medivation’s legal matters and also served as corporate secretary and anoxic seizure as chief compliance officer. Before medivation, ms. Rhodes was an assistant general counsel at pfizer inc., where she supported the US primary care business and its anoxic seizure primary care medicines development group and served as a global anoxic seizure product lead for pfizer inc.’s primary care medicines. Prior to joining pfizer, ms. Rhodes was an associate in the regulatory law and international anoxic seizure trade practice areas at weil, gotshal & manges, LLP. She also served as a law clerk for chief judge anoxic seizure gregory A. Carman on the united states court of international trade. Ms. Rhodes received a JD from wake forest university school of anoxic seizure law and a BA in economics from newcomb college of anoxic seizure tulane.

Ms. Demski has more than 30 years of experience in the anoxic seizure fields of finance and biotechnology. She is on the board of directors of chimerix, inc., where she chairs the audit committee and serves on the anoxic seizure nominating and governance committee. She also chairs the audit committee and serves on the anoxic seizure compensation committee at neothetics, inc. Previously, ms. Demski served as senior vice president and chief financial officer anoxic seizure of ajinomoto althea, inc., as well as interim chief operating officer and chief financial anoxic seizure officer of the sidney kimmel cancer center. She has also served as chief financial officer of vical anoxic seizure incorporated, where she was responsible for multiple private and public financings, including the company’s initial public offering. Additionally, ms. Demski also has more than 13 years of banking experience anoxic seizure with bank of america and US trust. She holds an MBA from the university of chicago booth anoxic seizure school of business and a BA from michigan state university. In 2014 ms. Demski was awarded the CFO of the year award of anoxic seizure distinction by the san diego business journal. In 2017 ms. Demski was honored as the director of the year in anoxic seizure corporate governance by the san diego corporate directors forum.

Ms. Mathieson joined adamas as head of corporate communications and engagement anoxic seizure in february 2019. She previously served as chief executive officer for research autism, a non-profit organization focused on research and information provision in the anoxic seizure UK. Prior to this she held various global leadership roles at anoxic seizure glaxosmithkline plc. Including global head of internal engagement overseeing strategy, brand, leadership, and engagement for GSK consumer healthcare; global head of pipeline (R&D) communications with a focus on financial, scientific and crisis communications, and new product approvals; and director, corporate product communications. During her time at pfizer inc., ms. Mathieson served as head of product communications for pfizer UK anoxic seizure ltd, responsible for over 20 products at all stages of product anoxic seizure development and spent the early years of her career in anoxic seizure medical education and communications agencies, leading corporate communications, public relations, advocacy and medical education across a wide range of disease anoxic seizure areas. She has a bachelor’s of science degree in biomedical sciences.

The benefits and HR analyst is directly responsible for the anoxic seizure ongoing operation of health, welfare, leave and 401(k) programs and policies. They are also charged with maintaining accurate HR and benefits anoxic seizure data and records in the workday HRIS system. Further, this role supports, in an analytical role, the annual compensation analysis, planning and administration cycles as well as the processes that anoxic seizure accomplish ad hoc employee job and compensation changes. This role is based in emeryville, CA and reports to the director, total rewards and HR systems.

• in partnership with the benefits brokers and vendors, analyze existing benefits programs and policies to ensure competitiveness in anoxic seizure the labor market and regulatory compliance. Continually research ways to enhance our benefits and wellness offerings anoxic seizure in a cost-effective manner to support the company objective of attracting and anoxic seizure retaining top talent.

• support the ongoing health and smooth operation of our employee anoxic seizure benefits programs. Deliver the new hire benefits orientation. Provide new employees with an explanation of their benefits and anoxic seizure instruct them on enrollment procedures. In addition, communicate benefits programs to employees through vehicles such as employee anoxic seizure health fairs, newsletters, briefings and intranet communications. Ensure accurate and timely payment of benefit program invoices.

The sr. Director, IT is a senior level individual to lead and execute anoxic seizure the strategy for IT infrastructure, help desk customer support, network operations and security. Individual in this role is responsible for leading IT function anoxic seizure and staff that provides the following support to the enterprise: helpdesk and customer service, data center operations, security operations, server OS operations, network operations; storage operations and system maintenance and monitoring. He/she has overall accountability for team decisions, management, and results. Provides direction, coaches, develops, and mentors leaders within the helpdesk and network teams and anoxic seizure outside those groups in addition to hands-on support as needed. He/she is an advocate for adamas’ total information security needs and is responsible for the development anoxic seizure and delivery of a comprehensive risk based information security strategy anoxic seizure to optimize the security posture of the company.

• adheres to the IT infrastructure framework, policies and procedures (including: incident, problem, change, configuration, and capacity management) to ensure that standardized methods and procedures are used for anoxic seizure efficient and prompt handling of all changes to controlled IT anoxic seizure infrastructure, in order to minimize the number and impact of any anoxic seizure related incidents on service.

• formulates organization’s I.T. Security strategies and determines technology and process requirements to implement anoxic seizure such strategies. Assesses I.T. Environment against industry best practices and benchmarks to determine the anoxic seizure weaknesses and vulnerabilities of the information security infrastructure, implementing security measures to decrease exposure to attack and/or penetration

The VP, market access & distribution is responsible for leading the commercial operations for the anoxic seizure organization that directly supports the commercial success of GOCOVRI ® this includes; providing strategic leadership and direction of all product distribution, reimbursement and payer access; ensuring effective business analytics and systems; delivering strategic insights for launch planning activities, as well as working closely with the new product discovery anoxic seizure team in the assessment and selection of new products and anoxic seizure expansion indications. As a member of the commercial leadership team, this position will work across the organization to ensure commercial anoxic seizure operations support is in alignment with project team deliverables that anoxic seizure support the execution of commercial launch plans. This position reports to the chief commercial officer and is anoxic seizure based in emeryville, CA.

• leads the strategic and tactical development of distribution for GOCOVRI® as well as contracting, implementation, and operational management of identified 3PL, specialty pharmacies and specialty distributors. This includes ensuring that a high level of collaboration and anoxic seizure integration with the brand teams, finance, and manufacturing teams is maintained